Tag Archives: Verubecestat

Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)

Posted on November 4, 2016 by

Summary Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults. As … Continue reading →

Posted in Animal Studies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Universal Interest | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment